



## City Research Online

### City, University of London Institutional Repository

---

**Citation:** Kanthou, C., Dachs, G. U., Lefley, D. V., Reyes-Aldasoro, C. C. & English, W. R. (2013). Endogenous VEGF isoform expression regulates tumour cell motility. Poster presented at the 2013 NCRI Cancer Conference, 03-11-2013 - 06-11-2013, Liverpool, UK.

This is the accepted version of the paper.

This version of the publication may differ from the final published version.

---

**Permanent repository link:** <https://openaccess.city.ac.uk/id/eprint/8373/>

**Link to published version:**

**Copyright:** City Research Online aims to make research outputs of City, University of London available to a wider audience. Copyright and Moral Rights remain with the author(s) and/or copyright holders. URLs from City Research Online may be freely distributed and linked to.

**Reuse:** Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

---

---

---

City Research Online:

<http://openaccess.city.ac.uk/>

[publications@city.ac.uk](mailto:publications@city.ac.uk)

---

# Endogenous VEGF isoform expression regulates tumour cell motility

Chryso Kanthou<sup>1</sup>, Gabriele Dachs<sup>2</sup>, Diane Lefley<sup>1</sup>, Constantino Carlos Reyes-Aldasoro<sup>3</sup>, William English<sup>1</sup>, Gillian Tozer<sup>1</sup>

<sup>1</sup>Tumour Microcirculation Group, Department of Oncology, School of Medicine, University of Sheffield, Sheffield, UK, <sup>2</sup>Mackenzie Cancer Research Group, Department of Pathology, University of Otago, Christchurch, New Zealand, <sup>3</sup>School of Engineering and Design, Biomedical Engineering Research Group, University of Sussex, Brighton, UK

## Background

Vascular endothelial growth factor-A (VEGF) is produced by most cancer cells as multiple alternatively spliced isoforms, which display distinct receptor and matrix binding characteristics. In addition to being a major inducer of tumour angiogenesis, VEGF also has complex functions in angiogenesis-independent aspects of tumour growth, but the role of individual VEGF isoforms remains poorly understood. Here we investigated the effects of endogenous VEGF isoform expression on tumour cell migration and invasion.

## Method

We used a panel of mouse fibrosarcoma cells we developed ( $fs^{188}$ ,  $fs^{164}$  and  $fs^{120}$ ) that express single VEGF isoforms (188, 164 or 120 respectively), under endogenous promoter control. We investigated adhesion to different matrices, 2D migration and invasion through 3D collagen.

## Results

$Fs^{188}$  cells, are typically mesenchymal, form ruffles, display strong integrin-dependent adhesion and express high levels of pERK1/2 and pAKT. In contrast,  $fs^{164}$  and  $fs^{120}$  cells are not typically mesenchymal in morphology; they display weak binding to collagen, lack ruffles and align longitudinally forming long multicellular chains and abundant cell-cell contacts. On 3D collagen,  $fs^{188}$  cells remain mesenchymal while  $fs^{164}$  and  $fs^{120}$  cells adopt a rounded/amoeboid and a mix of rounded/mesenchymal morphologies respectively. Cell morphology and migration are dependent on the cytoskeleton and actinomyosin contractility, to provide traction force in mesenchymal movement, and cortical contraction for rounded amoeboid motility. Consistent with their mesenchymal characteristics,  $fs^{188}$  cells migrated faster in 2D and invaded 3D collagen more efficiently than  $fs^{164}$  or  $fs^{120}$  cells. Contractility inhibitors caused  $fs^{164}/fs^{120}$  cells to switch to a mesenchymal morphology and accelerated their migration but not that of  $fs^{188}$  cells.

## Conclusion

VEGF isoforms are emerging as potential biomarkers for anti-VEGF therapies. Our results suggest that individual VEGF isoforms influence the migration and invasion strategies of tumour cells thus adding to the complexity of VEGF signaling within the tumor microenvironment.

## Acknowledgements

This work was funded by Cancer Research UK.

## References:

- [1] G. M. Tozer, S. Akerman, N. A. Cross, P. R. Barber, M. A. Björndahl, O. Greco, S. Harris, S. A. Hill, D. J. Honess, C. R. Ireson, K. L. Pettyjohn, V. E. Prise, C. C. Reyes-Aldasoro, C. Ruhrberg, D. T. Shima, and C. Kanthou, 'Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors', *Cancer Res.*, vol. 68, no. 7, pp. 2301–2311, Apr. 2008.
- [2] S. J. Lunt, S. Akerman, S. A. Hill, M. Fisher, V. J. Wright, C. C. Reyes-Aldasoro, G. M. Tozer, and C. Kanthou, 'Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate', *Int. J. Cancer J. Int. Cancer*, vol. 129, no. 8, pp. 1979–1989, Oct. 2011.